A history of repeated antibiotic usage leads to microbiota-dependent mucus defectsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether a history of repeated, but not recent, antibiotic use has lasting effects on the gut microbiota and on microbiota-mediated intestinal mucus barrier function. Researchers used human-to-mouse fecal microbiota transplantation to transfer gut microbial communities from previously antibiotic-exposed and healthy individuals into mice. They then measured mucus growth rate and mucus penetrability using ex vivo analyses of viable colonic tissue explants, and characterized the transplanted microbiota using shotgun metagenomic sequencing and metabolite profiling.
Who was studied?
The human source population was drawn from the deeply phenotyped Estonian Microbiome Cohort (EstMB), from which individuals with a history of repeated antibiotic use and healthy controls were selected for fecal sampling. The functional experiments were then carried out in mice that received fecal microbiota transplants from these human donors, so the mucus and microbiota outcomes reported reflect this humanized mouse model rather than direct measurements in the human donors themselves.
What were the most important findings?
Mice transplanted with microbiota from humans with a history of repeated antibiotic use showed a reduced mucus growth rate and increased mucus penetrability compared to mice given microbiota from healthy controls. Shotgun metagenomic sequencing showed the antibiotic-shaped microbial community had a significantly altered composition, with mucus-utilizing bacteria, including Akkermansia muciniphila and Bacteroides fragilis, dominating the gut. This altered microbiota was also marked by a distinct metabolite profile.
What are the greatest implications of this study?
The findings suggest that repeated antibiotic use can leave a lasting, microbiota-encoded imprint on the gut that impairs the mucus barrier long after the antibiotics themselves are gone. Because a healthy mucus layer normally protects the intestinal epithelium against infection and inflammation, this microbiota-driven thinning and increased penetrability could plausibly raise vulnerability to gut infection or inflammatory conditions. The dominance of mucus-utilizing organisms such as Akkermansia muciniphila and Bacteroides fragilis points to microbial mucus consumption as a candidate mechanism linking antibiotic history to barrier dysfunction, warranting further mechanistic study.